News Image

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

Provided By Globe Newswire

Last update: Jun 22, 2022

- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease  

- Initial pharmacodynamic results for two participants show unprecedented decreases in N-acetylaspartate (NAA) in the brain and urine, suggesting the therapy is producing functional ASPA enzyme 

Read more at globenewswire.com

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (5/27/2025, 8:03:04 PM)

After market: 33.29 +0.19 (+0.57%)

33.1

-0.24 (-0.72%)



Find more stocks in the Stock Screener

Follow ChartMill for more